Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

Shots: Witness the journey of the biopharma companies over 20 years with this informative and engaging report. The report highlights the development of the biopharma industry and the key factors influencing them In 2023, JNJ reclaims the topmost position in the list from Pfizer with a revenue of $85.16B, showcasing a sharp 10.30 percent vs…

BySaurabh ChaubeyMay 1, 2024

THOUGHTSPOT

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Shots: In the wake of International Labour Day, PharmaShots presents a detailed take on the recent layoffs in the Pharmaceutical Sector with an illustrative graphical analysis Like any sector, the pharmaceutical industry operates on some nuance and intricate aspects that ensure smooth operations. Factors like digitalization, patent expiry, growing competition, and others put direct or…

BySenior EditorMay 1, 2023

INSIGHTS+

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

Shots: With the indispensable transformations carried out over the years, the biopharma industry witnessed miraculous changes in operations, technology, and innovation. Such as inclination towards the Pharma 4.0 model, adoption of a multimodal building approach, and dependence on contract manufacturing While major companies like Johnson & Johnson, Roche, and Pfizer dominated the biopharma industry with…

BySenior EditorApril 13, 2023

INSIGHTS+

PharmaShots’ Key Highlights of Fourth Quarter 2022

Shots: The fourth quarter of 2022 highlights approvals, multiple clinical trial results, and numerous deals. There are major alliances in this quarter which include Johnson & Johnson acquired Abiomed for ~$16.6B, Takeda entered into an agreement to acquire NDI-034858 from Nimbus Therapeutics for ~$6B In the fourth quarter of the year, BeiGene’s Brukinsa received EC’s…

BySenior EditorDecember 29, 2022

TOP 20

Top 20 BioPharma Companies based on 2021 Total Revenue

While the COVID-19 pandemic has dominated the healthcare space for the last two years, some biopharma companies were involved in multiple deals, M&A, and the development of various drug candidates in other areas to diversify their portfolios While top Biopharma companies remain on the chart, however, in 2021, new players like Moderna, BioNTech, Viatris also…

ByPrince GiriApril 14, 2022

INSIGHTS+

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B,…

BySenior EditorSeptember 30, 2021

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2021

The US FDA has approved 7 NDAs and 1 BLA in Feb 2021, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 12 novel products in 2021. Additionally, last year in 2020, the US…

BySenior EditorMarch 18, 2021

INSIGHTS+

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemic Janssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased…

BySenior EditorJune 1, 2020

TOP 20

Top 20 BioPharma Companies based on 2019 Total Revenue

The global biopharma companies are developing novel therapies & devices which is- in turn- enhancing their portfolio and encouraging them in this undergoing competition to stay in the topmost position The top 20 companies chartbusters changed their 2019 ranking- but the history of Johnson and Johnson did not change and it continued being at the…

ByPrince GiriApril 24, 2020

INSIGHTS+

Insights+: Breakthrough Therapy Designation by the US FDA in 2019

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available…

BySenior EditorMarch 13, 2020

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2004-2023)

8 Major Reasons Behind the Soaring Layoffs in the Pharmaceutical Industry

Insights+: An Analysis of the Growth of Biopharma Companies in the Last 20 Years (2003-2022)

PharmaShots’ Key Highlights of Fourth Quarter 2022

Top 20 BioPharma Companies based on 2021 Total Revenue

PharmaShots’ Key Highlights of Third Quarter 2021

Insights+: The US FDA New Drug Approvals in February 2021

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Top 20 BioPharma Companies based on 2019 Total Revenue

Insights+: Breakthrough Therapy Designation by the US FDA in 2019

Contact US

FOLLOW US